Rapid Onset and Recovery Linezolid-Induced Thrombocytopenia: A Large-Sample, Single-Center Retrospective Cohort Study

Figures & data

Table 1 Study Inclusion and Exclusion Criteria

Inclusion Criteria	Exclusion Criteria
Patients aged 18 years or older Admitted to an inpatient ward from January 2017 to December 2022 Patients received intravenous linezolid for 48 hours or more Baseline platelet count ≥ 150,000/mm^3 Patient platelet count dropped by at least 50% or to <150,000/mm^3 within 14 days of starting linezolid therapy	Patients younger than 18 years Patients receiving intravenous linezolid for less than 48 hours Baseline platelet count <150,000/mm^3 Patient platelet count dropped by 50% or dropped to less than 150,000/mm^3 after 14 days of linezolid starting date Patient received oral linezolid Patient admitted before January 2017 or after December 2022

Table 2 Demographic Data of the Study Population

Parameter	Number	Percentage %	Parameter Mean	SD
Male	197	58.98
Female	137	41.01
Total	334
Population age			60.7	17.98
Creatinine clearance			67.5	58.45
Serum creatinine more than 1.5	146	43.71	3.401	1.86
Creatinine clearance below 60 mL/min	190	56.88	30.631	14.70
Creatinine clearance below 30 mL/min	96	28.74	18.260	6.20
Creatinine clearance below 15	30	8.982	11.33	2.52
ALT more than 98 IU/L	35	10.47	208.85	147.40
AST more than 68 IU/L	63	18.86	217.29	319.83
Platelet baseline more than 450 × 10^9/L	50	14.97	603.25	146.70
Platelet baseline 150–450 × 10^9/L	284	85.92	256.19	82.43
Patients showing recovery of thrombocytopenia within 14 days after linezolid discontinuation	92	46.93

Figure 1 Time to linezolid-induced thrombocytopenia.

Figure 2 Cumulative hazard for linezolid-induced thrombocytopenia.

Figure 3 Time to recovery from linezolid-induced thrombocytopenia.

Figure 4 Cumulative hazard for recovery from linezolid-induced thrombocytopenia after discontinuation.